{"id":"https://openalex.org/W2988085430","doi":"https://doi.org/10.1182/blood-2019-127603","title":"Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib","display_name":"Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2988085430","doi":"https://doi.org/10.1182/blood-2019-127603","mag":"2988085430"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-127603","doi":"https://doi.org/10.1182/blood-2019-127603","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-127603","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005565037","display_name":"Tanya Siddiqi","orcid":"https://orcid.org/0000-0001-5292-8298","observed_orcids":["https://orcid.org/0000-0001-5292-8298"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tanya Siddiqi","raw_affiliation_strings":["City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088343926","display_name":"Jacob Drobnyk Soumerai","orcid":"https://orcid.org/0000-0002-3062-6819","observed_orcids":["https://orcid.org/0000-0002-3062-6819"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacob D. Soumerai","raw_affiliation_strings":["Center for Lymphoma, Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Lymphoma, Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036343829","display_name":"Kathleen Anne Dorritie","orcid":"https://orcid.org/0000-0002-0863-8573","observed_orcids":["https://orcid.org/0000-0002-0863-8573"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathleen A. Dorritie","raw_affiliation_strings":["UPMC Hillman Cancer Center, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UPMC Hillman Cancer Center, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031412066","display_name":"Deborah Marie Stephens","orcid":"https://orcid.org/0000-0001-9188-5008","observed_orcids":["https://orcid.org/0000-0001-9188-5008"]},"institutions":[{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah M. Stephens","raw_affiliation_strings":["Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Huntsman Cancer Institute, University of Utah, Salt Lake City, UT","institution_ids":["https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004821244","display_name":"Peter A. Riedell","orcid":"https://orcid.org/0000-0003-2719-0580","observed_orcids":["https://orcid.org/0000-0003-2719-0580"]},"institutions":[{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter A. Riedell","raw_affiliation_strings":["University of Chicago Medical Center, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago Medical Center, Chicago, IL","institution_ids":["https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016770040","display_name":"Jon E. Arnason","orcid":"https://orcid.org/0000-0001-9038-7277","observed_orcids":["https://orcid.org/0000-0001-9038-7277"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jon E. Arnason","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, MA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036828560","display_name":"Thomas J. Kipps","orcid":"https://orcid.org/0000-0002-0064-4549","observed_orcids":["https://orcid.org/0000-0002-0064-4549"]},"institutions":[{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas J. Kipps","raw_affiliation_strings":["University of California San Diego Moores Cancer Center, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California San Diego Moores Cancer Center, San Diego, CA","institution_ids":["https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111783900","display_name":"Heidi H. Gillenwater","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heidi H. Gillenwater","raw_affiliation_strings":["Juno Therapeutics, a Celgene Company, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, a Celgene Company, Seattle, WA","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030806657","display_name":"Lucy Gong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lucy Gong","raw_affiliation_strings":["Juno Therapeutics, a Celgene Company, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, a Celgene Company, Seattle, WA","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112444514","display_name":"Jason A. Dubovsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason A. Dubovsky","raw_affiliation_strings":["Juno Therapeutics, a Celgene Company, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, a Celgene Company, Seattle, WA","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002278734","display_name":"Julie A. Rytlewski","orcid":"https://orcid.org/0000-0001-5244-6790","observed_orcids":["https://orcid.org/0000-0001-5244-6790"]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie Rytlewski","raw_affiliation_strings":["Juno Therapeutics, a Celgene Company, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, a Celgene Company, Seattle, WA","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101896989","display_name":"Lin Yang","orcid":"https://orcid.org/0000-0001-5379-6821","observed_orcids":["https://orcid.org/0000-0001-5379-6821"]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lin Yang","raw_affiliation_strings":["Juno Therapeutics, a Celgene Company, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, a Celgene Company, Seattle, WA","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089428686","display_name":"William G. Wierda","orcid":"https://orcid.org/0000-0002-7357-270X","observed_orcids":["https://orcid.org/0000-0002-7357-270X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William G. Wierda","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":31,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"503","last_page":"503"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.008899999782443047,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-chronic-lymphocytic-leukemia","display_name":"relapsed/refractory chronic lymphocytic leukemia","score":0.7710000276565552},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.9940000176429749},{"id":"https://openalex.org/keywords/lisocabtagene-maraleucel","display_name":"lisocabtagene maraleucel","score":0.9430000185966492},{"id":"https://openalex.org/keywords/cd19-car-t-cell-therapy","display_name":"CD19 CAR T-cell therapy","score":0.8389999866485596},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.7360000014305115},{"id":"https://openalex.org/keywords/high-risk-disease","display_name":"high-risk disease","score":0.6610000133514404},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.6570000052452087},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7149999737739563},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.421999990940094},{"id":"https://openalex.org/keywords/disease-free-survival","display_name":"disease-free survival","score":0.5009999871253967},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.4090000092983246}],"concepts":[{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.8316049575805664},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6780736446380615},{"id":"https://openalex.org/C2777609679","wikidata":"https://www.wikidata.org/wiki/Q5971015","display_name":"IGHV@","level":4,"score":0.5900633335113525},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.5802124738693237},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5521190166473389},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4619271159172058},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.4534674882888794},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3791976571083069},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36553144454956055},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3209277093410492},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.22497901320457458}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-127603","doi":"https://doi.org/10.1182/blood-2019-127603","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-127603","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2901100437","https://openalex.org/W2954848156","https://openalex.org/W2952207847","https://openalex.org/W3095280492","https://openalex.org/W4389231182","https://openalex.org/W2914082928","https://openalex.org/W3210008249","https://openalex.org/W4389232154","https://openalex.org/W7162539501","https://openalex.org/W4386282262"],"abstract_inverted_index":{"Background:":[0],"The":[1,340,396,467,646],"advent":[2],"of":[3,50,66,102,135,180,198,239,248,294,381,399,421,475,497,507,512,583,640,650,751,762,782,795,809,824,834,844,856,867],"oral-targeted":[4],"drugs":[5],"has":[6],"improved":[7],"treatment":[8],"outcomes":[9],"for":[10,160,224,228,549],"patients":[11],"(pts)":[12],"with":[13,31,70,77,113,137,269,296,435,509,587,622],"CLL.":[14],"Nonetheless,":[15],"some":[16],"pts":[17,69,76,139,203,221,240,255,301,308,312,358,367,422,498,547,567,586],"prove":[18],"intolerant":[19,285],"or":[20,86,97,127,276,753,764,784,797,811,826,846,858,869],"resistant":[21],"to":[22,26,286,379,530,537,543,577],"therapy":[23,268],"and/or":[24,184,417,554,571],"fail":[25],"achieve":[27],"complete":[28],"response":[29,484,501,528],"(CR)":[30],"uMRD.":[32],"Liso-cel":[33,189,288],"is":[34,60,653],"an":[35,61,213,748,759,779,792,806,821,841,853,864],"investigational,":[36],"anti-CD19,":[37],"defined":[38],"composition,":[39],"4-1BB":[40],"CAR":[41,54,190],"T":[42,55,153,191],"cell":[43],"product":[44],"administered":[45],"at":[46,81,87,177,304,309,316,472,610,656],"a":[47,105,178,246,874,888,900],"target":[48],"dose":[49,144],"CD4+":[51],"and":[52,150,208,226,266,281,306,331,383,390,401,408,425,445,460,539,594,600,606,617,631],"CD8+":[53],"cells.":[56,154],"TRANSCEND":[57],"CLL":[58,172],"004":[59],"open-label":[62],"phase":[63,636,647],"1/2":[64],"study":[65,642,652],"liso-cel":[67,141,464,602],"in":[68,182,292,321,337],"R/R":[71,588],"CLL/SLL":[72,78,589],"(NCT03331198).":[73],"Methods:":[74],"Eligible":[75],"had":[79,241,245,256,262,277,313,359,368],"received":[80,140,257,267,423,428,591],"least":[82,88],"3":[83,133,325,328,361],"(standard-risk":[84],"disease)":[85],"2":[89,143,532,648],"(high-risk":[90],"disease:":[91],"del[17p],":[92],"TP53":[93],"mutation,":[94],"unmutated":[95],"IGHV,":[96],"complex":[98],"karyotype)":[99],"prior":[100,252,258,592,598],"lines":[101],"therapy,":[103],"including":[104,374,604],"Bruton's":[106],"tyrosine":[107],"kinase":[108],"inhibitor":[109],"unless":[110],"contraindicated.":[111],"Pts":[112,244],"active":[114],"untreated":[115],"central":[116],"nervous":[117],"system":[118],"disease,":[119],"Eastern":[120],"Cooperative":[121],"Oncology":[122,955],"Group":[123],"performance":[124],"status":[125],">1,":[126],"Richter's":[128],"transformation":[129],"were":[130,147,158,165,193,210,222,273,284,302,348,608,619],"excluded.":[131],"After":[132],"days":[134,162,389,407],"lymphodepletion":[136],"fludarabine/cyclophosphamide,":[138],"infusion;":[142],"levels":[145],"(DLs)":[146],"tested:":[148],"DL1=50\u00d7106":[149],"DL2=100\u00d7106":[151],"CAR+":[152],"Dose-limiting":[155],"toxicities":[156],"(DLTs)":[157],"evaluated":[159,444],"28":[161],"postinfusion.":[163],"Responses":[164],"assessed":[166,176,211],"by":[167,195,457,502,563],"2018":[168],"International":[169],"Workshop":[170],"on":[171,264,747,758,778,791,805,820,840,852,863],"criteria.":[173],"MRD":[174],"was":[175,232,289,385,403,455,486,492],"sensitivity":[179],"\u226410-4":[181],"blood":[183,199,553,570],"bone":[185],"marrow":[186],"(BM)":[187],"lymphocytes.":[188],"cells":[192,200],"monitored":[194],"flow":[196],"cytometry":[197],"from":[201,526,533,541,634],"treated":[202,303],"over":[204,523],"time.":[205],"Serum":[206],"cytokines":[207],"chemokines":[209],"via":[212],"electrochemiluminescence":[214],"platform.":[215],"Results:":[216],"At":[217],"data":[218],"cutoff,":[219],"23":[220],"evaluable":[223,479,548],"safety":[225],"22":[227],"efficacy.":[229],"Median":[230,377],"age":[231],"66":[233],"(range,":[234,250,387,392,405,410],"49\u201279)":[235],"years;":[236],"83%":[237],"(19/23)":[238],"high-risk":[242],"disease.":[243],"median":[247,397,473],"5":[249,366,404],"2\u201211)":[251],"therapies.":[253],"All":[254,566],"ibrutinib;":[259,280],"56.5%":[260],"(13/23)":[261],"progressed":[263],"ibrutinib":[265,593],"venetoclax;":[270],"91%":[271],"(21/23)":[272],"refractory":[274],"to,":[275],"relapsed":[278],"on,":[279],"9%":[282],"(n=2)":[283],"ibrutinib.":[287],"successfully":[290],"manufactured":[291],"96%":[293],"pts,":[295,480,520],"the":[297,481,488,635,641,651],"established":[298],"process.":[299],"Nine":[300],"DL1":[305],"14":[307],"DL2.":[310,657],"Two":[311,357],"DLTs":[314],"(all":[315,590],"DL2:":[317],"grade":[318,324,327,332,343,360,369],"4":[319,333,386,391],"hypertension":[320],"1":[322,338,540,637],"pt;":[323],"encephalopathy,":[326],"muscle":[329],"weakness,":[330],"tumor":[334,432],"lysis":[335],"syndrome":[336,364],"pt).":[339],"most":[341,551],"common":[342],"3/4":[344],"treatment-emergent":[345],"adverse":[346],"events":[347,372],"thrombocytopenia,":[349],"70%;":[350],"anemia,":[351],"96%;":[352],"neutropenia,":[353],"56.5%;":[354],"leukopenia,":[355],"43.5%.":[356],"cytokine":[362],"release":[363],"(CRS);":[365],"\u22653":[370],"neurological":[371],"(NEs),":[373],"encephalopathy":[375],"(n=3).":[376],"time":[378,524],"onset":[380,454],"CRS":[382,400,416,605],"NE":[384,402,436,453],"1-10)":[388],"2-21)":[393],"days,":[394,412],"respectively.":[395,413],"duration":[398],"2-30)":[406],"21":[409],"6-169)":[411],"To":[414],"manage":[415],"NE,":[418,607],"61%":[419],"(n=14)":[420],"tocilizumab":[424],"48%":[426],"(n=11)":[427],"corticosteroids.":[429],"Lymph":[430],"node":[431],"burden":[433],"correlated":[434],"(P=0.025).":[437],"Additional":[438],"disease":[439,535],"distribution":[440],"correlates":[441],"are":[442],"being":[443],"will":[446,643],"be":[447,644],"presented.":[448],"Cytokine":[449],"analyses":[450],"revealed":[451],"that":[452],"preceded":[456],"elevated":[458],"TNF\u03b1":[459],"IL16":[461],"early":[462],"after":[463],"infusion":[465],"(P<0.01).":[466],"table":[468],"shows":[469],"best":[470,482,489],"responses":[471,521,624],"follow-up":[474,514],"9":[476],"months.":[477,627],"Among":[478,545],"overall":[483],"rate":[485,491],"82%;":[487],"CR/CRi":[490],"45.5%.":[493],"Sixty-eight":[494],"percent":[495],"(15/22)":[496],"achieved":[499,552,560,569],"objective":[500],"Day":[503,564],"30;":[504],"78%":[505],"(7/9)":[506],"responders":[508],"\u22659":[510],"months":[511],"postdose":[513],"have":[515,574],"remained":[516,575],"progression-free.":[517],"In":[518,580],"6":[519,626],"deepened":[522],"(3":[525],"partial":[527],"[PR]":[529],"CR,":[531],"stable":[534],"[SD]":[536],"PR,":[538],"SD":[542],"CR).":[544],"20":[546],"MRD,":[550],"BM":[555,561,572],"uMRD":[556,562,573,576,618],"(Table);":[557],"60%":[558],"(12/20)":[559],"30.":[565],"who":[568],"date.":[578],"Conclusions:":[579],"this":[581],"population":[582],"heavily":[584],"pretreated":[585],"half":[595],"failed":[596],"both":[597,611],"venetoclax":[599],"ibrutinib),":[601],"toxicities,":[603],"manageable":[609],"DLs":[612],"tested.":[613],"Objective":[614],"responses,":[615],"CRs,":[616],"rapidly":[620],"achieved,":[621],"durable":[623],"past":[625],"Updated":[628],"safety,":[629],"pharmacokinetic,":[630],"efficacy":[632],"results":[633],"monotherapy":[638],"part":[639],"reported.":[645],"portion":[649],"currently":[654],"enrolling":[655],"Disclosures":[658],"Siddiqi:":[659],"Kite,":[660],"A":[661],"Gilead":[662,919],"Company:":[663,876,890,902],"Research":[664,668,671,682,688,698,701,704,707,714,718,721,724,727,730,738,743,767,787,800,814,829,905,908,912,917,921,924,928,931,935,940,943,946,949,952,957],"Funding;":[665,669,672,699,705,708,715,725,728,744,788,801,815,830,906,909,913,918,922,925,929,932,936,941,944,947,950,953],"TG":[666,716],"Therapeutics:":[667,693,927],"Celgene:":[670,756],"Janssen:":[673,951],"Speakers":[674,678,684,690,734,740],"Bureau;":[675,679,685,691,735,741],"Seattle":[676],"Genetics:":[677],"AstraZeneca:":[680],"Consultancy,":[681,687,694],"Funding,":[683,689,739],"PCYC:":[686],"Juno":[692,926],"Other:":[695],"travel":[696],"support,":[697],"BeiGene:":[700],"Funding.":[702,719,722,731,768,958],"Soumerai:BeiGene:":[703],"BostonGene:":[706],"AbbVie:":[709],"Consultancy;":[710,712,772],"Verastem:":[711,745,861],"Genentech/Roche:":[713],"therapeutics:":[717],"Dorritie:Juno:":[720],"Stephens:Karyopharm:":[723],"Gilead:":[726],"Acerta:":[729],"Riedell:Bayer:":[732],"Honoraria,":[733,737,776,838],"Kite/Gilead:":[736],"Novartis:":[742],"Membership":[746,757,777,790,804,819,839,851,862],"entity's":[749,760,780,793,807,822,842,854,865],"Board":[750,761,781,794,808,823,843,855,866],"Directors":[752,763,783,796,810,825,845,857,868],"advisory":[754,765,785,798,812,827,847,859,870],"committees;":[755,848,860],"committees,":[766,786,799,813,828],"Arnason:Regeneron":[769],"Pharmaceuticals,":[770],"Inc.:":[771,803,850,939,956],"Celgene/Juno:":[773],"Consultancy.":[774],"Kipps:Pharmacyclics:":[775],"Abbvie:":[789],"Genentech,":[802],"Velos-Bio:":[816],"Equity":[817,878,882,892,896],"Ownership,":[818],"Jannsen":[831],"Pharmaceutical":[832],"Companies":[833],"Johnson":[835],"&":[836],"Johnson:":[837],"AstraZeneca,":[849],"committees.":[871],"Gillenwater:Juno":[872],"Therapeutics,":[873,887,899],"Celgene":[875,889,901],"Employment,":[877,881,891],"Ownership.":[879,883,897],"Gong:Celgene:":[880],"Dubovsky:Celgene:":[884],"Employment.":[885,903],"Rytlewski:Juno":[886],"Ownership;":[893],"Adaptive":[894],"Biotechnologies:":[895],"Yang:Juno":[898],"Wierda:AbbVie:":[904],"Genentech:":[907],"Pharmacyclics":[910],"LLC:":[911],"Acerta":[914],"Pharma":[915],"Inc:":[916],"Sciences:":[920],"Xencor:":[923],"Sunesis:":[930],"KITE":[933],"pharma:":[934],"Oncternal":[937],"Therapeutics":[938],"Miragen:":[942],"GSK/Novartis:":[945],"Cyclcel:":[948],"Loxo":[954]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":14}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-11-22T00:00:00"}